# Nutex Health Inc. (NUTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Technology / Software. Price $193.24, market value $1.3 billion.

## Valuation
- **P/E (trailing): 7.5×** (5-yr avg 9.5×, 3-yr avg 9.5×). Nutex Health Inc. trades at 7.5× trailing earnings, well below its own five-year average of 9.5×: cheap by its own standards. The Technology median in the September 2026 study was 32.1×. Forward P/E is 9.5×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 1.17**. A PEG of 1.17 is in the range usually read as fairly priced for its growth.
- **Price / sales: 1.6×**. Each dollar of revenue is priced at 1.6×.
- **Price / book: 3.4×**. The shares trade at 3.4× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 3.1×**. Enterprise value is 3.1× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 20.7%** (5-yr avg 7.5%). Free cash flow equals 20.7% of the market value, above its five-year average of 7.5%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 13.4%**. The inverse of the P/E: 13.4% of the price is earned each year.

## Profitability
- **Gross margin: 51.3%**. Nutex Health Inc. keeps 51.3% of revenue after the direct cost of what it sells.
- **Operating margin: 43.0%**. 43.0% of revenue is left after running the business, an exceptional level.
- **Net margin: 8.1%**. 8.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 21.5%**. 21.5% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 154.4%**. Return on all capital, debt included, is 154.4%: comfortably above what that capital costs.
- **Return on assets: 19.6%**. Each dollar of assets produces 19.6% of profit.

## Growth
- **Revenue growth (1 yr): 82.4%** (3-yr 58.6%/yr, 5-yr 26.1%/yr). Revenue grew 82.4% over the last year, against 26.1% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 8.2%** (5-yr 125.4%/yr). Earnings per share rose 8.2%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 89.7%/yr**. Free cash flow has compounded at 89.7% a year over three years.

## Financial health
- **Debt to equity: 0.13**. Debt is 0.13 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Nutex Health Inc. holds more cash than debt.
- **Altman Z-score: 4.05**. A Z-score of 4.05 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Nutex Health Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Nutex Health Inc.; the consensus is strong_buy, with an average price target of $283.00 (+46% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 125.0%** (YTD 17.4%, 3-mo 45.7%). The shares are up 125.0% over twelve months including dividends.
- **From 52-week high: -5.3%** (140.0% above the low). Trading 5% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 2.18** (volatility 93%). Beta of 2.18 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NUTX · Page: https://foliofundamentals.com/stocks/nutx

Not investment advice.